| 1 |
35457111 | The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. | 2022 Apr 13 |
1 |
| 2 |
34210314 | Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds. | 2021 Jul 1 |
1 |
| 3 |
32352244 | Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. | 2020 Jul |
1 |
| 4 |
33376736 | Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis. | 2020 |
2 |
| 5 |
30577988 | PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. | 2019 Sep |
1 |
| 6 |
31069145 | Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. | 2019 |
2 |
| 7 |
31552290 | PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. | 2019 |
1 |
| 8 |
29223745 | Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2018 Jan |
1 |
| 9 |
29472518 | Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. | 2018 May 15 |
2 |
| 10 |
30241001 | Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. | 2018 Nov |
1 |
| 11 |
28036259 | Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. | 2017 Jan 24 |
3 |
| 12 |
28725277 | SABCS 2016: systemic therapy for metastatic breast cancer. | 2017 |
1 |
| 13 |
26715098 | Targeting the PI3K signaling pathway in KRAS mutant colon cancer. | 2016 Feb |
2 |
| 14 |
27426307 | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. | 2016 Sep |
2 |
| 15 |
26289070 | Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. | 2015 Dec 15 |
1 |
| 16 |
25285632 | An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells. | 2014 Oct 24 |
1 |